Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-4-17
|
pubmed:abstractText |
The binding of luteinizing hormone-releasing hormone (LH-RH) analogues to the human mammary tumor cell line MCF-7 and their effect on the cell proliferation was studied to elucidate their direct action on estrogen-dependent mammary tumors. The growth rate of these cells was doubled by the addition of 1 nM estradiol to cells maintained in an estrogen-deficient medium. Although the basal growth rate was only slightly inhibited by the LH-RH antagonist [Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)3,D-Cit6,D-Ala10]LH-RH (SB-75), the estrogen-stimulated growth was completely abolished by the antagonist. In contrast, the LH-RH agonist buserelin stimulated cell growth in estrogen-deficient medium, whereas it had no effect in the presence of estrogen. 125I-labeled buserelin was used for the measurement of LH-RH receptors on MCF-7 cells. A Scatchard plot analysis of buserelin-specific binding revealed a nonlinear plot, which suggested the presence of one high-affinity binding site with a Kd of 1.4 +/- 1.0 nM and the remaining sites with low affinity (Kd = 1.3 +/- 1.0 microM). The binding of 125I-labeled buserelin was displaced equally well by unlabeled buserelin and by the LH-RH antagonist SB-75, suggesting that both analogues are bound to the same receptor. When parallel experiments were performed with 125I-labeled SB-75, the binding was displaced by unlabeled SB-75 and other antagonists, but only partially displaced by unlabeled buserelin. The results suggest that in these mammary tumor cells there is a LH-RH antagonist binding site that is not recognizable by LH-RH agonists. This hypothesis was tested by measuring cell growth in the presence of both agonists and antagonists. It was found that SB-75 inhibited the stimulation of growth by buserelin, but buserelin did not prevent the inhibition by the antagonist of the estrogen-dependent growth. These results suggest that antagonists directly inhibit mammary tumor growth, not only by competing with LH-RH high-affinity receptors, but also by other mechanisms mediated by low-affinity antagonist binding sites.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-2194783,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-2569034,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-2646641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-2982100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3029154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3082618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3119199,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3278323,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3304294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3549276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-3802100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-6254391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-6269924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-6443575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1312718-6461861
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Buserelin,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, LHRH,
http://linkedlifedata.com/resource/pubmed/chemical/Triptorelin Pamoate,
http://linkedlifedata.com/resource/pubmed/chemical/cetrorelix
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0027-8424
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
89
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2336-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1312718-Antineoplastic Agents,
pubmed-meshheading:1312718-Breast Neoplasms,
pubmed-meshheading:1312718-Buserelin,
pubmed-meshheading:1312718-Cell Division,
pubmed-meshheading:1312718-Dose-Response Relationship, Drug,
pubmed-meshheading:1312718-Estradiol,
pubmed-meshheading:1312718-Female,
pubmed-meshheading:1312718-Gonadotropin-Releasing Hormone,
pubmed-meshheading:1312718-Humans,
pubmed-meshheading:1312718-Kinetics,
pubmed-meshheading:1312718-Receptors, LHRH,
pubmed-meshheading:1312718-Triptorelin Pamoate
|
pubmed:year |
1992
|
pubmed:articleTitle |
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
|
pubmed:affiliation |
Clinical Biochemistry Department, Faculty of Health Sciences, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|